Pre‑market ticker buzz

Traders were watching tiny premarket moves in a handful of stocks on April 16, while JPMorgan Chase’s first-quarter report set the tone for the new earnings season. (jpmorganchase.com) JPMorgan reported first-quarter 2026 net income of $16.5 billion, or $5.94 a share, on reported revenue of $49.8 billion. The bank said its Markets division generated $11.6 billion of revenue, up 20% from a year earlier. (jpmorganchase.com) In premarket trading on April 16, Tesla was up about 0.5% at 9:30 a.m. Eastern time, trading at $393.85 versus a prior close of $391.95. Nvidia was modestly lower in early trading, with Morningstar showing the stock at $197.16 at 6:45 a.m. after a $198.88 previous close. (public.com) (morningstar.com) That mix of bank earnings and minute-by-minute stock moves is typical of the first days of earnings season, when investors use big-bank results as an early read on trading activity, deal flow and credit conditions. Reuters said on April 16 that major United States banks had delivered a split picture, with trading helped by volatility while dealmaking stayed under pressure. (usnews.com) The smaller tickers in traders’ feeds were moving on company-specific catalysts rather than broad market themes. Immutep, a clinical-stage biotechnology company, disclosed this week that the United States Food and Drug Administration granted orphan-drug designation for eftilagimod alfa in soft-tissue sarcoma. (marketwatch.com) (immutep.com) Immutep was also still trading in the shadow of a much larger collapse earlier in April. Investor-law-firm notices published on April 15 said the company’s shares had lost roughly 80% to 90% after it disclosed that an independent committee recommended halting the Phase III TACTI-004 lung-cancer trial for futility. (prnewswire.com) (globenewswire.com) Google Finance showed Immutep at $0.54 in early trading on April 16, with a premarket price of $0.56. That left the stock as a low-priced biotech name where a regulatory update could draw attention even after a steep recent selloff. (google.com) VisionSys AI, listed on Nasdaq under the ticker VSA, is an American depositary share listing that had traded at $2.90 on October 27, 2025, according to Nasdaq’s company page cached by search results. Current live pricing was not fully accessible through Nasdaq’s site in this search, but the ticker is tied to a small-cap artificial-intelligence name that can attract speculative premarket interest. (nasdaq.com) By the opening bell, the thread running through the chatter was simple: one giant bank had already posted numbers, and traders were using every small move in Tesla, Nvidia, Immutep and VisionSys AI as a clue to what the rest of earnings season might bring. (jpmorganchase.com) (usnews.com)